Acorda Therapeutics News
Most Popular Acorda Therapeutics Story
FDA approves Acorda's new MS drug
The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated Read more...
Latest Headlines
- May 20, 2011
- February 10, 2010
- January 25, 2010
- January 22, 2010
- October 15, 2009
- October 14, 2009
- October 9, 2009
- July 1, 2009
- April 23, 2009
- March 31, 2009
- February 27, 2009
- April 9, 2008
- July 25, 2007
- December 7, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
